OrbusNeich Honored with 2026 Asia Pacific Enterprise Awards and Asia Responsible Enterprise Awards

(Hong Kong, August 10, 2026) – OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a multinational medical device company specializing in interventional solutions for percutaneous coronary intervention (“PCI”) and percutaneous transluminal angioplasty (“PTA”) procedures, has been awarded the “Corporate Excellence Award” at the Asia Pacific Enterprise Awards (“APEA”) 2026 China and the “Health Promotion Award” at the Asia Responsible Enterprise Awards (“AREA”) 2026 China, both organized by Enterprise Asia.

These dual accolades not only recognize the Group’s excellence in global operations but also reaffirm OrbusNeich’s belief that business value and social value can reinforce one another to create long-term impact.

Amid a complex and evolving global market environment, the Group continues to advance product innovation and technological upgrades while strengthening its global strategic partnerships and expanding its international sales network. This long-term, fundamental-driven approach has enhanced OrbusNeich’s operational resilience and risk management capabilities, aligning closely with the APEA Corporate Excellence Award’s emphasis on innovation, business robustness, and global strategy.

Building on a strong business foundation, OrbusNeich actively invests in physician development. Through its Physician Exchange Program (PEP), experienced specialists share practical clinical expertise, particularly in complex cases such as CTOs, with local physicians across Asia, facilitating regional knowledge exchange. At the same time, the Annual Scientific Congress and Exchange for Next Generation Interventionalists (ASCENT) provides a professional development platform for young physicians, fostering the transfer and advancement of clinical knowledge. This dual approach, combining horizontal knowledge exchange and vertical physician development, has contributed to improving regional healthcare standards and formed a key basis for the Group’s recognition with the AREA Health Promotion Award.

Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, “We are honored to receive this dual recognition from Enterprise Asia in the same year. These awards are a strong affirmation of our belief in ‘Excellence in management, advancing interventional cardiology toward patient-centered care.’ We firmly believe that only by maintaining a strong and resilient business can we create meaningful impact for society. Looking ahead, we will continue to strengthen our PEP and the ASCENT, integrate global resources, support the development of medical professionals, and enable innovative technologies to transcend geographical boundaries and reach more patients.”

Enterprise Asia is a leading non-governmental organization dedicated to creating an Asia rich in entrepreneurship as an engine for sustainable and progressive economic and social development. Through its programs, the organization promotes entrepreneurship, develops business leaders, and advances responsible business practices across the region. The Asia Pacific Enterprise Awards (APEA) recognize outstanding entrepreneurs and enterprises for excellence in entrepreneurship and business leadership, while the Asia Responsible Enterprise Awards (AREA) honor organizations that demonstrate exemplary commitment to corporate sustainability and responsible business practices.

OrbusNeich awarded the “Corporate Excellence Award” at the 2026 Asia Pacific Enterprise Awards and Asia Responsible Enterprise Awards China Chapter

－ End －

About OrbusNeich Medical Group Holdings Limited
OrbusNeich is a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, our Group sells its products in more than 70 countries and regions worldwide. It is also actively expanding into structural heart disease. With an in-house R&D team boasting over 20 years of product development expertise, our Group has developed world-leading proprietary technologies.

For more information, please visit the Group’s official website: https://orbusneich.com/.